SLU-PP-332

SLU-PP-332 is a groundbreaking synthetic pan-estrogen-related receptor (ERR) agonist developed at Saint Louis University that functions as an exercise mimetic. It activates the same metabolic pathways your body engages during physical exercise without requiring actual physical activity. By enhancing mitochondrial biogenesis, fatty acid oxidation, and energy expenditure, SLU-PP-332 produces remarkable metabolic and performance effects across multiple organ systems.

MECHANISM OF ACTION

SLU-PP-332 binds to and activates estrogen-related receptors (ERRα, ERRβ, ERRγ), with preferential activity at ERRα. This activation upregulates PGC-1α, the master regulator of mitochondrial biogenesis, and activates the AMPK pathway (the cellular energy switch). The result is increased mitochondrial density up to 1.8-fold, enhanced oxidative phosphorylation and ATP production, promotion of fatty acid oxidation, induction of type IIa oxidative muscle fiber genes, and activation of acute aerobic exercise genetic programs — all without physical activity.

POTENTIAL BENEFITS

• Exercise mimetic effects without physical activity requirement

• Significant weight loss (12% in 28 days in animal studies)

• 70% increased endurance capacity

• 25% enhanced fatty acid oxidation

• Improved insulin sensitivity and glucose control

• Reduced hepatic steatosis (fatty liver)

• Cardiac protection and improved cardiac function

• Reversal of age-related mitochondrial dysfunction

• Enhanced muscle oxidative capacity and metabolic flexibility

• Kidney protection and reduced age-related kidney decline
  

WHY IT'S BEING RESEARCHED

SLU-PP-332 is being studied because it represents a novel pharmacological approach to metabolic health that bypasses the need for physical exercise. Recent landmark studies show it produces weight loss comparable to GLP-1 agonists, reverses age-related mitochondrial dysfunction in kidneys, and improves metabolic syndrome markers without severe side effects. This makes it compelling for sedentary populations, aging research, and metabolic disease intervention.

INTERESTING FACTS

• 2024 landmark study showed 12% body weight loss in 28 days with <0.5g fat mass gain versus ~5g in controls

• 2023 study demonstrated reversal of age-related kidney decline, restoring mitochondrial architecture via electron microscopy

• Increases mitochondrial density up to 1.8-fold through PGC-1α upregulation

• 2.3-fold selectivity for ERRα over ERRβ and 4.4-fold over ERRγ

• Well-tolerated in rodents and canines with no liver, kidney, or cardiac toxicity observed

• Animal studies used 4-8 week protocols with twice-daily dosing

• Requires DMSO for solubility (insoluble in water)

• Effects appear within days in animal models, peak by 2-4 weeks
  

STACKING

Common research combinations include:

• Metformin for complementary metabolic enhancement — SLU-PP-332 activates ERR/AMPK while metformin enhances mitochondrial function through different pathways. Monitor blood glucose closely as combined use could increase hypoglycemia risk.

• Tirzepatide or Semaglutide for synergistic weight loss and metabolic improvement — combining exercise mimetics with GLP-1 agonists produces additive weight loss and insulin sensitivity effects. Early research suggests complementary mechanisms with no documented negative interactions.

• NAD+ for enhanced mitochondrial support — both upregulate mitochondrial biogenesis and NAD metabolism. Potential for synergistic anti-aging effects.

• SS-31 (Elamipretide) for comprehensive mitochondrial optimization — SS-31 protects the inner mitochondrial membrane while SLU-PP-332 increases mitochondrial density. Complementary mechanisms with no known interactions.

• MOTS-C for synergistic metabolic and longevity effects — both activate mitochondrial pathways and improve metabolic health through different mechanisms.

RESEARCH PURPOSES ONLY

NOT AVAILABLE FOR HUMAN CONSUMPTION